Summary We evaluated the effect of parathyroid hormone (PTH) on Wnt10b production by immune system cells in humans. We showed that bone anabolic effect of intermittent PTH treatment may be amplified by T cells through increased production of Wnt10b. Chronic increase in PTH as in primary hyperparathyroidism does not increase Wnt10b expression. Introduction The aim of this study is to assess the effect of PTH on Wnt10b production by immune system cells in humans. We assessed both the effect of intermittent PTH administration (iPTH) and of chronic PTH hypersecretion in primary hyperparathyroidism (PHP). Methods Eighty-two women affected by post-menopausal osteoporosis were randomly assigned to treatment with calcium and vitamin D alone (22) or plus 1-84 PTH (42), or intravenous ibandronate (18). Wnt10b production by unfractioned blood nucleated cells and by T, B cells and monocytes was assessed by real-time RT-PCR and ELISA at baseline, 3, 6, 12 and 18 months of treatment. The effect of chronic elevation of PTH was evaluated in 20 patients affected by PHP at diagnosis and after surgical removal of parathyroid adenoma.
Introduction
Parathyroid hormone (PTH) regulates calcium and phosphate homeostasis and has profound effects on bone turnover. PTH chronic increase, as in primary or secondary hyperparathyroidism, has catabolic effects on bone, causes bone loss and increases fracture risk [1] . In contrast, intermittent PTH injection has anabolic effects on bone [2] and prevents fragility fractures; indeed, intermittent PTH is currently used for the treatment of post-menopausal osteoporosis [3, 4] .
The PTH receptor (PPR) is mainly expressed in the bone and kidney, but its expression has also been reported in other tissues where it likely reflects the local paracrine role of PTHrelated protein [5] [6] [7] . In the bone, PPR is expressed in osteoclasts [8] and mainly in cells of osteoblastic lineage as osteocytes [9] . A recent work by Saini et al. [9] suggests that osteocytes are necessary for intermittent PTH anabolic effects. Treatment with intermittent PTH activates Wnt signalling pathway in osteoblast by suppressing sclerostin production by osteocytes [10] [11] [12] [13] [14] [15] [16] .
PPR is also expressed by T cells [17] , which are required for intermittent PTH to exert its bone anabolic effect as recently demonstrated in mice [17] [18] [19] . The bone anabolic response to intermittent PTH is blunted in the absence of T cells and is restored by adoptive transfer of these cells [17, 18] . T cells mediate intermittent PTH anabolic effect on bone through the upregulation of Wnt10b on their surface [18] ; Wnt10b interacts with osteoblasts upregulating Wnt pathway and induces bone formation.
Unlike intermittent PTH, continuous PTH infusion, a condition that mimics primary hyperparathyroidism (PHP) in humans, does not affect Wnt10b expression by T cells in mice [17, 18] , whereas in humans no data are available.
Here, we show that PTH affects Wnt10b production by immune system cells in humans, potentially explaining its anabolic effect.
Materials and methods

Patients
The study was approved by the Ethical Committee of the A.O.U. Città della Salute e della Scienza -A.O. Ordine Mauriziano -A.S.L. TO1, Turin, Italy, and informed consent was obtained from all participants. The study population was recruited from the patients of A.O.U. Città della Salute e della Scienza, Turin, Italy, and healthy volunteers. The study included patients affected by post-menopausal osteoporosis and patients affected by PHP.
Post-menopausal osteoporosis
Eighty-two women affected by post-menopausal osteoporosis without fractures were randomly allocated to treatment with:
i. intermittent PTH (PTH 1-84 100 mcg/day s.c.-Preotact®, kindly provided by Nycomed-plus calcium 1200 mg/day and colecalcipherol 800 UI/day, referred to hereafter as iPTH), 42 patients, ii. calcium and vitamin D 1200 mg/day and colecalcipherol 800 UI/day (referred to hereafter as calcium and vitamin D), 22 patients, and iii. intravenous ibandronate 3 mg every 3 months, plus calcium and vitamin D (referred to hereafter as IB), 18 patients.
This is a parallel, randomized controlled, open-label, trial (registered as PTH1-84 EudraCT 2009-012397-12). The randomization was done by computer-generated tables to allocate treatments. Randomization was done by the principal investigator, patients were enrolled by participants in the study and lab measurement and statistical analyses were done in blind to treatment.
Patients affected by secondary osteoporosis or taking drugs active on bone metabolism were not considered eligible for the study.
Blood samples from patients were collected at baseline and after 3, 6, 12 and 18 months of treatment.
Primary hyperparathyroidism
We enrolled in the study 20 patients (16 women and 4 men) affected by PHP, none of them were affected by diseases affecting bone health other than PHP. Subjects with secondary hyperparathyroidism, severe vitamin D deficiency, chronic renal disease (GFR<60) and any other condition known to affect PTH levels were excluded.
The diagnosis of PHP was established on the finding of elevated circulating levels of calcium and PTH in at least two instances and the presence of normal renal function. PHP patients were subjected to parathyroidectomy and restoration of normal parathyroid function was demonstrated by the finding of normal serum PTH and calcium levels 1 month after surgery. Blood samples were collected at baseline and 1 month after parathyroidectomy.
Healthy controls
Two groups of healthy subjects were enrolled as controls for post-menopausal women (31 healthy post-menopausal women) and for PHP patients (42 healthy men and women in postmenopausal period or in fertile age). Patients and controls were matched for sex, age and years since menopause.
The study design is summarized in Fig. 1 . The demographic characteristics of the study population are shown in Table 1 .
Measurements of Wnt10b mRNA
Wnt10b mRNA was measured in unfractioned peripheral blood nucleated cells in osteoporotic patients, in PHP and in healthy controls. Unfractioned peripheral blood nucleated cells were obtained by red blood cells lyses, the obtained cells were frozen at −80°C until RNA extraction. In 36 osteoporotic patients (18 treated with iPTH and 18 with IB), T cells, B cells and monocytes were separated by immunomagnetic beads separation (Stemcells Technology) to evaluate which cell produces Wnt10b (Fig. 1) .
Real-Time PCR (RT-PCR) was used to evaluate Wnt10b expression. RNA was isolated using TRIzol reagent (Ambion, Huntingdon, UK), chloroform extraction and subsequent isopropanol precipitation according to the manufacturer's protocol. One microgram of RNA was converted up to singlestranded cDNA by the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). RT-PCR was performed with IQ SYBR Green Supermix (BIORAD). The housekeeping control gene was β-Actin and gene expression was quantified through 2−ΔΔCt method. The primers used were the following: 5′-CCATGACATGGACTTTGGAGAG -3′ (forward), 5′-CTGGAATCCAAGAAATCCCG -3′ (reverse) for Wnt10b and 5′-CCTAAAAGCCACCCCACTTCT -3′ (forward) and 5′-CACCTCCCCTGTGTGGACTT -3′ (reverse) for β-Actin. Fig. 1 The diagram shows the study design. The number of patients in each group and the experiments done in each visit are specified 
Statistical analyses
Wnt10b values were not normally distributed according to kurtosis normality test; hence, the effect of treatment on its expression was evaluated by repeated measure tests, after logarithmic transformation. Wnt10b mRNA levels were analysed by Mann-Whitney (healthy controls vs. osteoporotic or PHP) and Wilcoxon matched pairs signed-rank tests (PHP vs. PHP after surgery and different cell types). The sample size provided an 80 % power, assuming a twosided significance level of 0.05, to detect differences in Wnt10b of 3-fold, according with the results obtained in mice [18] .
The statistical analyses were performed through SPSS 21.0 and graphs were designed through Prism Graph Pad 6.0.
Results
Osteoporosis does not affect Wnt10b production by blood nucleated cells
To evaluate whether Wnt10b expression was decreased in osteoporosis, we compared its expression in unfractioned blood nucleated cells from osteoporotic patients and healthy women, matched for age and postmenopausal period. Wnt10b was not significantly different between patients and controls (Fig. 2a) , suggesting that it is not involved in the pathogenesis of postmenopausal osteoporosis.
iPTH increases Wnt10b production by T cells
Treatment with iPTH in osteoporotic women increases Wnt10b gene expression in peripheral blood nucleated cells, whereas calcium and vitamin D alone do not (Fig. 2b) . In particular Wnt10b increases of approximately 21-fold after 6 months of treatment and returned to baseline values after 18 months (Fig. 2b) . Fig. 2 Wnt 10b expression in osteoporosis and during treatment. a Levels (median mean±SE) of Wnt10b mRNA in healthy controls (n= 31) and osteoporotic subjects (n=46). Data were analysed by MannWhitney as the data were not normally distributed according to the kurtosis normality test. b Wnt10b mRNA fold change versus baseline in osteoporotic patients treated with iPTH (n= 21) or calcium and vitamin D (n=20). Data were analysed by multiple measurement test after logarithmic transformation, as the data were not normally distributed according to the kurtosis normality test. c Wnt10b protein production by unfractioned blood nucleated cells in osteoporotic patients treated with iPTH (n=21) or calcium and vitamin D (n=20). Data were analysed by multiple measurement test after logarithmic transformation, as the data were not normally distributed according to the kurtosis normality test. d Serum BAP in osteoporotic patients treated with iPTH (n=21) or calcium and vitamin D (n=20). Data were analysed by multiple measurement test Wnt10b protein level, detected by ELISA, confirmed an increase of Wnt10b production during treatment with iPTH ( Fig. 2c) , according to the RT-PCR results. The increase in Wnt10b mimics the observed rise in bone alkaline phosphatase (BAP, Fig. 2d ) that is a well-known bone formation marker.
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The analyses of separated T, B cells and monocytes as compared to unfractioned blood nucleated cells revealed that T cells are the main responsible for Wnt10b expression in osteoporotic patients without treatment, whereas B cells and monocytes only express a small amount of this molecule (Fig. 3a) . Further evaluation of T cells during iPTH treatment compared to IB reveals that the increase of Wnt10b expression depend on iPTH; indeed, IB does not induce any significant variation (Fig. 3b) . B cells and monocytes do not increase Wnt10b expression during treatment (Fig. 3c, d ).
Chronic elevation of PTH did not increase Wnt10b expression
Wnt10b was not increased in unfractioned peripheral blood nucleated cells from patients affected by PHP compared to healthy controls (Fig. 4) ; nevertheless, surgical restoration of normal parathyroid function decreased Wnt10b expression of about 36 %.
Even though surgical intervention decreased Wnt10b, its expression remains not significantly different as respect to healthy controls (Fig. 4) . All the surgical intervention were completely successful as demonstrated by the fall in PTH level from 136±26 to 68± 8 ng/mL, p=0.008.
Discussion
This study explores the effect of iPTH and PHP on Wnt10b production by T cells in humans, we show that T cells are the main producers of Wnt10b amongst peripheral blood nucleated cells, and Wnt10b expression increases during iPTH treatment. These data suggest that T cells may mediate the anabolic action of iPTH in humans as they do in mice [17, 18] . According to this hypothesis, literature data derived from animal models report that the anabolic activity of iPTH depends on T cells, which increase the expression of Wnt10b [17, 18] . Indeed, treatment with iPTH in mice stimulates T cell production of Wnt10b that increases osteoblastogenesis. T celldeficient mice or mice with T cell-knock out for Wnt10b display a blunted bone anabolism after treatment with iPTH [17] .
The analysis of Wnt10b expression in peripheral blood nucleated cells, at different time during iPTH treatment, allows us to create a Wnt10b curve that reveals an increase in its expression that is maximal 6 months after treatment. This increase was not observed in patients treated with calcium and vitamin D alone. The Wnt10b curve in response to iPTH mimics the well-known bone anabolic markers curve [3, 4] , confirming Wnt10b role in mediating iPTH anabolic action.
Differently from iPTH, chronic elevation of PTH, as in PHP, does not increase Wnt10b expression. However, 1 month after surgical intervention, Wnt10b expression results significantly decreased, but comparable to healthy subjects. This result may depend on the small size of the cohort analysed, but we speculate a possible effect of chronic elevation in PTH on Wnt10b that is not sufficient to increase it above normal range. To support this hypothesis, literature data report that chronic elevation of PTH in PHP modulates Wnt signalling pathway also by suppressing SOST in humans [20, 21] as well as in mice [22] .
This observation may explain the anabolic effect on trabecular bone of PHP; indeed, PHP preferentially involves cortical bone with preservation of cancellous areas, as demonstrated by histomorphometric analysis. In particular, the majority of patients with PHP showed reductions in cortical width, whereas the cancellous compartment of the bone biopsy specimen showed greater than average values for trabecular bone volume, trabecular number, connectivity and separation, indicating preservation of this bone compartment in most patients with PHP [23] [24] [25] [26] . Here, we describe a decrease in Wnt10b, after surgical restoration of normal parathyroid function, which may partially explain the anabolic effect of PHP on trabecular bone.
Our study has a number of strengths: to our knowledge, this work represents the first study in humans to evaluate the effect of PTH on peripheral blood nucleated cells with particular regard to T cells. In addition, we attempted to do so without in vitro culture of the cells, which could substantially alter their gene expression and other characteristics. Patients and controls have been carefully matched for potential confounders and randomized to different treatment group. However, one major limitation of our work is the small sample size especially of PHP cohort.
In conclusion, this study reports that PTH induces an increase of Wnt10b production by T cells in humans. Thus, our data suggest that T cells amplify the anabolic effect of PTH on bone.
